SIGHT.PA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 11:35):

Stats
Today's Volume	23 048.00
Average Volume	154 023
Market Cap	32.62M
EPS	€0 ( 2024-04-05 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.770
ATR14	€0.00300 (0.72%)

Gensight Biologics SA Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Gensight Biologics SA Financials

Annual	2023
Revenue:	€1.27M
Gross Profit:	€3.00M (236.78 %)
EPS:	€-0.540

Q4	2023
Revenue:	€1.45M
Gross Profit:	€124 000 (8.55 %)
EPS:	€-0.280

Q3	2023
Revenue:	€124 000
Gross Profit:	€124 000 (100.00 %)
EPS:	€-0.140

Q2	2023
Revenue:	€1.55M
Gross Profit:	€1.36M (87.61 %)
EPS:	€-0.260

Financial Reports:

No articles found.

Gensight Biologics SA

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.